- Home
- RDCM vs SABS Comparison
RDCM vs SABS Comparison
Compare RDCM & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | SABS |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.7M | 201.4M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | RDCM | SABS |
|---|---|---|
| Price | $11.20 | $3.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $18.00 | $9.80 |
| AVG Volume (30 Days) | 82.5K | ★ 262.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.50 | N/A |
| Revenue Next Year | $9.74 | N/A |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $1.00 |
| 52 Week High | $15.14 | $6.60 |
Technical Indicators
Market Signals| Indicator | RDCM | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 39.83 | 43.42 |
| Support Level | $10.77 | $3.75 |
| Resistance Level | $13.40 | $4.16 |
| Average True Range (ATR) | 0.50 | 0.27 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 21.54 | 38.69 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.